- Home
- INBK vs URGN Comparison
INBK vs URGN Comparison
Compare INBK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- URGN
- Stock Information
- Founded
- INBK 1999
- URGN 2004
- Country
- INBK United States
- URGN United States
- Employees
- INBK N/A
- URGN N/A
- Industry
- INBK Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- INBK Finance
- URGN Health Care
- Exchange
- INBK Nasdaq
- URGN Nasdaq
- Market Cap
- INBK 196.2M
- URGN 181.2M
- IPO Year
- INBK N/A
- URGN 2017
- Fundamental
- Price
- INBK $27.59
- URGN $14.24
- Analyst Decision
- INBK Buy
- URGN Strong Buy
- Analyst Count
- INBK 4
- URGN 8
- Target Price
- INBK $34.50
- URGN $29.00
- AVG Volume (30 Days)
- INBK 45.0K
- URGN 4.1M
- Earning Date
- INBK 07-23-2025
- URGN 08-12-2025
- Dividend Yield
- INBK 0.86%
- URGN N/A
- EPS Growth
- INBK 27.37
- URGN N/A
- EPS
- INBK 2.40
- URGN N/A
- Revenue
- INBK $114,609,000.00
- URGN $91,871,000.00
- Revenue This Year
- INBK $5.36
- URGN $36.65
- Revenue Next Year
- INBK $17.09
- URGN $88.35
- P/E Ratio
- INBK $11.57
- URGN N/A
- Revenue Growth
- INBK 20.13
- URGN 8.98
- 52 Week Low
- INBK $19.54
- URGN $3.42
- 52 Week High
- INBK $43.27
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- INBK 63.75
- URGN 64.26
- Support Level
- INBK $27.09
- URGN $13.55
- Resistance Level
- INBK $28.51
- URGN $14.66
- Average True Range (ATR)
- INBK 0.90
- URGN 0.83
- MACD
- INBK 0.07
- URGN -0.08
- Stochastic Oscillator
- INBK 82.27
- URGN 73.66
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.